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Abstract
Background: Peritoneal metastasis (PM) is the second
most common site of recurrence in colon cancer (CC)
patients and accounts for approximately one-third of all
recurrences. Patients with T4 or intraperitoneal perfo-
rated colon cancers have an increased risk of developing
PM, and since manifest PM is difficult to treat, high-risk
patients should be offered prophylactic treatment. Here,
we propose a study of adjuvant oxaliplatin administered
as pressurized intraperitoneal aerosol chemotherapy
(PIPAC OX) in patients with high-risk colon cancer (T4,
perforated tumors, ovarian metastasis).
Methods: PIPAC-OPC3 CC is a non-randomized, non-
blinded phase 2 cohort study designed to treat high-risk
colon cancer patients with adjuvant PIPAC-directed ther-
apy. Based on an expected 90% peritoneal recurrence-free
survival with adjuvant PIPAC against the estimated 75%
without, 60 patients are needed (α: 0.05, power: 0.8).
Eligible patients will receive two PIPAC treatments with
oxaliplatin (92mg/m2) at 4–6 week intervals. During
laparoscopy, the peritoneum is biopsied at two locations,
and peritoneal lavage with 500mL of saline and laparo-
scopic ultrasound is performed. The patients are screened
for adverse medical events and surgery-related complica-
tions after each PIPAC procedure. After the second PIPAC
procedure, the patients will be examined in the outpatient
clinic and followed with CT scans 12, 24 and 36 months
after resection. The primary outcome of the PIPAC-OPC3
CC trial is to evaluate if PIPAC-directed adjuvant therapy
can reduce the risk of PM. Secondary outcomes include the
number of conversions from positive to negative peritoneal
lavage cytology after one PIPAC procedure, completion
rate of two adjuvant PIPAC treatments, toxicity and com-
plication rate and recurrence-free and overall survival
rates after 1, 3 and 5 years.
Results: It is expected that PIPAC-directed adjuvant ther-
apy can provide an absolute risk reduction of 15%
regarding the development of PM in high-risk colon
cancer patients, and that this may result in increased
survival rates. We expect that free intraperitoneal tumor
cells (FITC) may be detected by peritoneal lavage
performed just prior to the administration of PIPAC-
directed therapy, and that this treatment may convert
FITC-positive patients to a FITC-negative status.
Conclusions: This study may provide important knowl-
edge to be used in designing additional studies on PIPAC
in the adjuvant setting of other primary cancers.
Trial registration: ClinicalTrials.gov Identifier NCT03280511
(2017-09-12). European Clinical Trials Database (EudraCT)
2017-002637-37.
Keywords: adjuvant PIPAC, high-risk, colon cancer,
resection, peritoneal metastasis.
Introduction
Despite curative intended surgery and perioperative che-
motherapy in patients with colon cancer, relapse is often
encountered, and across tumor stages recurrence is
found in 18–26% of the resected patients [1, 2]. Eighty-
six percent of the recurrences are diagnosed within 3
years after resection and 36% within the 1 year regard-
less of tumor stage [1]. The route of dissemination varies
between different cancer types, but a common denomi-
nator is the risk of peritoneal metastasis (PM). PM is the
second most common site of recurrence in colon cancer
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patients and accounts for 25–35% of all recurrences [3,
4]. Patients with PM – both in the synchronous and in
the metachronous setting – will often have a very short
life expectancy [5] and traditionally, treatments have
been nihilistic due to poor performance status and
response rates, and most patients with peritoneal recur-
rence will only be treated with best supportive care [4].
During the last two decades, more aggressive treatment
strategies have been implemented, including extensive
surgery (cytoreductive surgery, CRS) followed by
hyperthermic intraperitoneal chemotherapy (HIPEC) [6,
7]. However, CRS and HIPEC are only used in selected
patients with limited PM.
High-risk factors for relapse with PM have been
identified, and patients with T4 colon cancers have a
risk of relapse with metachronous PM between 12 and
50% [8–11], while patients with intraperitoneally per-
forated colorectal cancers relapse with PM in 14–58%
of the cases [12–14]. The risk of metachronous PM in
perforated or T4 colorectal cancers has been validated
[15] and widely recognized in the ongoing European
trials, where adjuvant HIPEC is being investigated to
reduce the risk of metachronous PM [16] (www.clinical
trials.gov: NCT02231086, NCT02965248, NCT02614534,
NCT02974556, NCT01226394).
Free intraperitoneal tumor cells (FITCs) are perceived
as a precursor of PM, and it is expected that patients with
perforated/T4 colon cancer will have FITC prior to visible
recurrence with PM. However, despite the reported
impact on the risk of recurrence and poor survival data
[17], the presence of FITC is not routinely investigated,
and this may be due to the lack of treatment options
regarding the eradication of free tumor cells. In a sys-
tematic review of resected patients with stage I-IV color-
ectal cancer, 13.7% had FITC detected at perioperative
peritoneal lavage. The rate of FITC increased with
increasing T-stage [18] and FITC held a significantly
increased risk of both local and overall recurrence, plus
a significantly increased mortality [19].
Due to the above-mentioned rates of recurrences after
resection of high-risk colon cancer and the limited treat-
ment options, new treatment strategies are needed.
Pressurized IntraPeritoneal Aerosol
Chemotherapy (PIPAC)
PIPAC is a new drug delivery system that may be used in
patients with manifest PM [20]. PIPAC is a safe procedure
with a very low adverse event profile [21–25] and without
any risk to healthcare personnel as long as certain safety
precautions are used [25]. Preliminary clinical experience
shows promising results in PIPAC-directed treatment of
patients with PM from several different types of primary
cancer including colorectal [20]. However, the potential
use of PIPAC-directed therapy in the adjuvant setting (i. e.
following R0 resection) has not been evaluated.
Detection of FITC
FITC is usually detected by analyzing smears of sediment
from the peritoneal lavage fluid collected during a sta-
ging laparoscopy or during the course of surgery. As FITC
is routinely investigated in especially Asian gastric can-
cer patients, the current experience on the detection of
FITC arises mainly from studies in gastric cancer patients.
A recent meta-analysis described the risk of peritoneal
recurrence of gastric cancer, based on analysis of perito-
neal lavage fluid [26]. In this study, peritoneal lavage
cytology predicted peritoneal recurrence with a sensitiv-
ity of only 0.45, while the specificity was 0.92–0.98. By
the detection of carcinoembryonic antigen (CEA) in the
peritoneal lavage fluid, the sensitivity was 0.77 and the
specificity 0.89, whereas the analysis of CEA mRNA
raised the sensitivity to 0.87, with a specificity of 0.80
[26]. In a systematic review, peritoneal lavage cytology
predicted the peritoneal recurrence of gastric cancer
patients with a sensitivity of 0.11–0.80 and a specificity
of 0.86–1.00 [27]. By analyzing the lavage fluid with
immunoassays, immunohistochemistry or reverse tran-
scriptase polymerase chain reaction (RT-PCR) mainly
towards CEA, the sensitivity and specificity still varied
significantly (sensitivity 0.23–1.00, specificity 0.81–0.98).
Despite the variable results, the included studies con-
firmed a significantly reduced median overall survival
in patients with FITC. However, there is no standard
definition of the techniques or cut-off points used to
detect FITC – neither in gastric/gastroesophageal junc-
tion (GEJ) cancer patients nor in colon cancer patients.
Aim
Primary and secondary outcomes
The primary outcome of this trial is the proportion of
patients with peritoneal recurrence diagnosed with con-
trast enhanced CT of the thorax and abdomen 36 months
after resection of their high-risk colon cancer. Secondary
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outcomes include (1) the number of conversions from
positive to negative peritoneal lavage cytology after one
PIPAC procedure, (2) completion rate of two adjuvant
PIPAC treatments, (3) treatment-related toxicity and com-
plication rate, (4) 1- and 2-year peritoneal recurrence-free
survival, based on CT of the thorax and abdomen, (5) 1-, 2-
and 3-year recurrence-free survival based on CT of the
thorax and abdomen and (6) 1-, 3- and 5-year overall
survival rate.
Methods
Recruitment process
Radically resected patients with colonic adenocarcinoma or signet
ring cell carcinoma and high-risk tumors (perforated/pT4NanyM0
(UICC 8th edition)/pTanyNanyM1 with radically resected PM includ-
ing ovarian metastases) are eligible for inclusion (Table 1). Prior to
inclusion, the patients will be discussed at a dedicated PIPAC multi-
disciplinary tumor conference (MDT). The patients will be treated
according to international guidelines with 3 or 6 months adjuvant
systemic chemotherapy, and then scheduled for adjuvant PIPAC OX
2–4 weeks after completion of the systemic chemotherapy. In
selected cases, systemic chemotherapy is not an option (patient
refusal, allergies etc.), and then the patients will be scheduled for
PIPAC 2 months after resection.
Study intervention and procedures
Included patients will be scheduled for two adjuvant PIPAC proce-
dures with intervals of 4–6 weeks (Figure 1). When the patient is
enrolled, a baseline CT of the thorax and abdomen is performed to
rule out recurrence before intervention. A laparoscopic ultrasound
(LUS) is also performed during the first PIPAC procedure to rule out
any (abdominal) recurrence that may have been missed during
baseline CT [28].
Diagnostic laparoscopy
In general anesthesia and following prophylactic antibiotics, a diag-
nostic laparoscopy is performed through two standard trocars,
where insufflation of normothermic CO2 maintains an intraabdom-
inal pressure of 12 mmHg. Unexpected PM or suspicious lesions will
be biopsied and sent for frozen section evaluation.
Peritoneal lavage (PL)
Five-hundred milliliters of saline will be administered into the perito-
neal cavity through a standard irrigation and suction device with
100mL delivered in the right subphrenic area, 100mL in the right
paracolic gutter, 100mL in the left paracolic gutter, 100mL in the
epigastrium and 100mL in the pelvis. The patient is then rotated to
the anti-Trendelenburg position and 200mL fluid is collected, and
referred for further examination, while the remaining fluid will be
collected and disposed. The fluid will be centrifuged, and smears of
the sediment will be analyzed by conventional cytology
(Papanicolaou and May–Giemsa Grünwald staining). Leftovers of
the sediment are embedded in paraffin wax. If appropriate, as judged
by the pathologist and based on the findings at conventional cytol-
ogy, sections from the paraffin-embedded material will be used for
immunocytochemical analyses for tumor markers, such as CEA,
EpCAM, CDX2 and/or CK20 as well as markers for mesothelial cells,
such as calretinin and vimentin, on 4 μm thick sections from the
paraffin block. Moreover, mRNA from the sediment will be analyzed
using RT-PCR for mRNA of markers such as CEA, CK20 and Ep-CAM.
To minimize the risk of false-positive detection of FITC, positive
Table 1: Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
– Radically resected patients with colonic adenocarcinoma or signet
ring cell carcinoma with high-risk tumors defined as: perforated/
pTNanyM (UICC th edition)/pTanyNanyM with radically
resected PM including ovarian metastases
– Performance status –
– Age > years
– Fertile women must use contraceptives
– Written informed consent
– Radiologically or clinically proven relapse
– Previous CRS with HIPEC
– Other malignant diagnoses within the last  years
– Contraindications to laparoscopy (e. g. severe adhesions, peritonitis)
– A history of allergic reaction to oxaliplatin- or other platinum-
containing compounds
– Renal impairment, defined as GFR <mL/min, (Cockcroft-Gault
Equation)
– Myocardial insufficiency, defined as NYHA class >
– Impaired liver function defined as bilirubin ≥ . ×UNL (upper
normal limit)
– Inadequate hematological function defined as ANC ≤ . x /L
and platelets ≤  ×/L
– Any other condition or therapy that in the investigator’s opinion
may pose a risk to the patient or interfere with the study
objectives
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peritoneal lavage cytology is crucial in the diagnosis of FITC. Still, if
cytology with immunocytochemical analyses demonstrates atypical
cells and mRNA CEA levels are increased, the patient is categorized as
having FITC, since increased mRNA CEA levels alone lead to a sig-
nificantly increased risk of developing PM [26].
Histology
Two peritoneal biopsies ( < 5 g) will be analyzed by a dedicated
gastrointestinal pathologist, to rule out visually undetected malig-
nancy. No protocol-specific analyses will be made, and if malig-
nancy is detected, the tissue will be evaluated according to the
department’s PIPAC guidelines, which are based on evaluation of
the Peritoneal Regression Grading Score (PRGS), using H&E-stained
slides and immunostaining of EpCAM [29]. If necessary, immunos-
taining for other markers will be performed, based on the judgement
of the pathologist, which also is in accord with the department’s
standard PIPAC guidelines.
PIPAC
PIPAC is performed through a CE-certified nebulizer (CapnoPen,
Gothia Medical, Billdal, Sweden), using oxaliplatin at a dose of
92mg/m2. The chemotherapy is installed at a rate of 30mL/min
with a maximum pressure of 200 pound-force per square inch and
after 5min, the chemotherapy has been delivered, and the injector
is turned off. After an additional 25min of simple diffusion,
intraabdominal CO2 is evacuated in a closed system, and the
patient is closed according to the department’s PIPAC guidelines.
Dose and administration is based on available studies where
PIPAC with oxaliplatin have been used for treating PM of color-
ectal origin. Dose modification can be made in case of adverse
reactions (Table 2).
Post-procedure monitoring
Post-operative monitoring and treatment of nausea, vomiting and
pain will be according to departmental guidelines. The patient will
Before Protocol 
Resection of colonadeno- or 
signet ring cell carcinoma: 
- pT4NanyM0 
- pTanyNanyM1 with
radically resected 
PM including 
ovarian metastases 
Adjuvant systemic 
chemotherapy (if indicated) 
Inclusion of patients 
CT thorax+abdomen 
Laparoscopy (LUS, PL, 
biopsies, PIPAC 1) 
Laparoscopy (PL, biopsies, 
PIPAC 2) 
CT thorax+abdomen 12, 24, 
36 months after resection 
Recurrence. Exluded and discussed 
at the multi-disciplinary tumor
conference.
Q 4–6 weeks 
Figure 1: Patient flow chart.
LUS: laparoscopic ultrasound, PL: peritoneal lavage, PM: peritoneal metastasis.
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be discharged the same day or the first day after the PIPAC proce-
dure. After the first PIPAC procedure, the patient will be contacted
by telephone after approximately 2 weeks, to screen for adverse
reactions and give information on the cytology and histology and
to plan the second PIPAC procedure. Adverse medical events will be
graded according to the Common Terminology Criteria for Adverse
Events (CTCAE, version 4.0) and surgery-related complications
according to the Dindo-Clavien classification. The second PIPAC
treatment will be given after 4–6 weeks. During this laparoscopy,
biopsies and PL will be repeated. After two PIPAC procedures, the
patients will be examined in the outpatient clinic, to screen for
adverse reactions and give information on the cytology and histol-
ogy. After this visit, the patients will be scheduled for follow-up with
CT of the thorax and abdomen 12, 24 and 36 months after resection.
The patient file and radiology reports will be evaluated after 1, 3
and 5 years according to primary and secondary outcomes. The
active treatment period is 2 months and then the patient will be
followed for a total of 3 years, meaning that the last contact will be
after the 36-month post-operative CT scan.
Study design
This is a non-randomized, non-blinded phase 2 cohort study
designed to treat high-risk colon cancer patients with adjuvant
PIPAC.
Ethical declarations
This study is GCP monitored and has been approved by the Regional
Scientific Ethical Committees for Southern Denmark (IRB S-
20170106) and the Danish Medicines Agency (case no 2017063403,
EudraCT 2017-002637-37). Oral and written consent from participants
are mandatory.
Statistics
Values are given as means or medians where appropriate.
Categorical data will be specified with 95% confidence intervals,
comparisons will be performed using non-parametric tests, all p
values are two-tailed and a p value of 0.05 will be considered
statistically significant. Survival will be modelled in Kaplan–Meier
analyses.
Results and discussion
Hypothesis and power calculation
As PIPAC seems to have an effect on visible PM in colon
cancer patients, we hypothesize that PIPAC can minimize
the risk of PM recurrence in resected high-risk colon
cancer patients. Furthermore, we expect that PIPAC can
eradicate FITC in these patients. An estimated 25% of
patients with a pT4 or perforated primary colon tumor
are expected to develop PM. Based on the preliminary
results of PIPAC, we expect an absolute risk reduction of
15% in the adjuvant setting. To evaluate this difference
(90% peritoneal recurrence-free survival with adjuvant
PIPAC against the estimated 75% without) a total of 54
patients are needed (two-sided, α: 0.05, power: 0.8). With
an expected dropout rate of 10%, a total of 60 patients
will be included.
Interim analysis
An interim analysis will be performed when 20 patients
have completed both PIPAC treatments to test if PIPAC has
been able to eradicate FITC detected by peritoneal lavage
cytology and/or RT-PCR. If FITC is eradicated in at least
one patient, it will be interpreted as a proof of efficacy and
the study will continue. If there are no patients with FITC
after the treatment of 20 patients, it will be evaluated
whether the timing of intervention after resection or the
methods of peritoneal lavage fluid analysis have to be
changed. If FITC is detected, but eradication does not
occur in at least one patient after treatment of 20 patients,
the type or dosage of intraperitoneal chemotherapy will be
changed or the study will be terminated.
Author contributions: All the authors have accepted
responsibility for the entire content of this submitted manu-
script and approved submission.
Study schedule: The trial started inclusion of patients in
December 2017. Inclusion and treatment of the last patient
is expected by March 2020. All data generated or analyzed
during this study will be included in the published article(s).
Table 2: Dose modification during PIPAC therapy.
Adverse reaction Action
Grade  No modification
Grade  If the toxicity is tolerable for the patient,
the planned treatment will continue. If the
toxicity is poorly tolerated, the dose of
oxaliplatin will be reduced to %.
Grade  The treatment will be postponed until the
toxicity is below grade . After this,
oxaliplatin can be given in a dose of %.
Grade  Stop treatment. Treatment can be reinstituted
at the discretion of the responsible physician,
if the adverse reaction falls below grade 
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Trial organization: The trial is organized by Odense
PIPAC Center (OPC) which is a multi-disciplinary cancer
group based at Odense University Hospital.
Research funding: This study was funded by Odense
PIPAC Center (OPC) and Odense Pancreas Center (OPAC),
Region of Southern Denmark, Odense University Hospital,
5000 Odense, Denmark.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played
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